A randomised, double-blind, crossover study to compare the effects of exenatide and sitagliptin on postprandial glucose in subjects with type 2 diabetes mellitus

Trial Profile

A randomised, double-blind, crossover study to compare the effects of exenatide and sitagliptin on postprandial glucose in subjects with type 2 diabetes mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2015

At a glance

  • Drugs Exenatide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Sep 2008 Primary and secondary endpoint results presented at EASD 2008 according to Amylin Pharmaceuticals media release.
    • 01 Apr 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 07 Nov 2007 The expected completion date for this trial is now 1 Jan 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top